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April 2, 2013:1461–8The claim that patients receiving more aggressive ablation
protocols (including ablation of complex fractionated electro-
grams) would be more likely to benefit from colchicine treatment
is obviously an issue to be determined by future research. However,
our data do not show an interaction between the ablation of
complex fractionated electrograms and the reduction of AF recur-
rence by colchicine. On a more general note, our findings seem to
be independently corroborated by a similar smaller study from
Japan, presented in the 2012 American Heart Association Scien-
tific Sessions by Egami et al. (2), showing that a 2-week course of
colchicine resulted in less AF recurrences after ablation for
paroxysmal AF. As for the conjecture of Filgueiras-Rama et al.
that “other substrates such as persistent AF, [. . .] might benefit
from using colchicine to prevent AF recurrences after the proce-
dure,” it might be true, but we are not aware of any existing
evidence to support it. From a pathophysiological point of view,
one would actually expect anti-inflammatory treatment to be less
effective in persistent or permanent AF, where structural substrate
factors are known to play a prominent part in AF recurrence and
perpetuation, than in paroxysmal AF, where substrate alterations
are expected to be less marked.
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American College of Cardiology
Foundation Recommendations
Assume Incorrectly That Cardiac
Troponins T and I Are Equally
Cardiac Specific
The American College of Cardiology Foundation (ACCF), in
collaboration with the American Heart Association and other
organizations, has produced recommendations designed to helpclinicians with the practical interpretation of elevated cardiac
troponin (1). The document can be regarded as a companion to the
also recently published “Third Universal Definition of Myocardial
Infarction” (2). By necessity, the recommendations in the 2
documents are harmonized. This unfortunately also means that a
fundamental error in one has been repeated in the other. Both
documents refer to cardiac troponin (cTn) as one entity and make
no distinction between cTnT and cTnI. Elevation of either marker
in the circulation is viewed as virtually diagnostic of myocardial
necrosis. There are important biological and analytical differences
between the 2 cardiac troponins that directly affect diagnosis and
decision making.
The first point to make is that cTnT, unlike cTnI, is not cardiac
specific. During fetal development, cTnT exists in both cardiac
and skeletal muscles (3,4). After birth, it gradually disappears from
skeletal muscle, such that healthy skeletal muscle in adults (and
children) do not contain either cTnT or cTnI. However, when
skeletal muscle is injured, it repairs itself by regeneration, a process
that recapitulates embryonic myogenesis and causes re-expression
of fetal proteins, including cTnT. Thus, diseased skeletal muscle
contains cTnT in addition to skeletal troponins T and I (5,6).
The second issue regards the claim that the Roche (Mannheim,
Germany) cTnT analyzer is cardiac specific despite the analyte not
being organ specific. It was previously thought that the 2 antibod-
ies of the assay would apparently not be able to detect cTnT in
diseased skeletal muscle, based on a study of patients with
end-stage renal disease (7). It was assumed that the same would
hold true for patients with skeletal muscle diseases in general,
although no similar studies were performed in this group of
patients. The validation study of the newly introduced high-
sensitivity cTnT assay (8) simply showed that its 2 antibodies did
not cross react with skeletal troponins, which is insufficient for
claiming cardiac specificity. The central question of whether the
assay cross reacts with cTnT or its isoforms in diseased skeletal
muscle was not addressed.
There are clinical and laboratory evidence to show the Roche
assay cannot distinguish between cTnT from cardiac muscle and
that from diseased skeletal muscle. Whereas injury to myocardium
causes the simultaneous release of both cTnI and cTnT into the
circulation, chronic injury to skeletal muscle causes the release of
cTnT but not cTnI, as predicted by their different biological
expressions (9–11). The characteristic biochemical profile of pa-
tients with skeletal myopathies consists of persistent elevation of
creatine kinase, creatine kinase myocardial band, and cTnT but
normal cTnI, and N-terminal pro–B-type natriuretic peptide (12).
Western blot studies on skeletal muscle biopsies have confirmed
that the antibodies used in the Roche’s standard and high-
sensitivity assays are not cardiac specific, but are also immunore-
active against cTnT (or its isoforms) found in diseased skeletal
muscle (13).
Elevation of cTnT in the blood can have dual clinical
significance—myocardial damage or skeletal muscle repair. The
ACCF and other organizations will need to amend their recom-
mendations to take account of the fundamental differences be-
tween cTnI and cTnT.
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Elevated Troponin
and Aortic Valve Disease
I read with great interest the recent paper by Newby et al. (1) on
interpretation of troponin elevations. The investigators discuss a
considerable variety of disease states but leave out an important
cause of troponin elevation: aortic valve disease.
A decade ago, aortic valve disease patients were shown to
frequently have elevated troponin I values (2). This finding was
subsequently confirmed by Kupari et al. (3). Aortic valve disease
may manifest itself through chest pain, and may be one of thecauses for a false diagnosis of myocardial infarction. It is important
to point out that, on the whole, the syndrome of chest pain,
elevated troponin levels, but no significant coronary artery disease,
is not a benign condition (4).
Apart from diagnostic considerations, troponin may also have
prognostic significance in this context. Rosjo et al. (5) showed that
elevated troponin levels had prognostic implications in patients
with aortic valvular stenosis. Solberg et al. (6) studied symptomatic
aortic stenosis patients and found that high-sensitive troponin T
and N-terminal–brain natriuretic peptide predicted outcomes.
Troponin may therefore be an important biomarker in the
evaluation of patients with aortic valve disease.
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Troponins Should Be
Confirmed With CK-MB
in Atypical Presentations
Newby et al. (1) provide a timely reminder of the importance of
pre-test probability in the interpretation of any diagnostic test
result, particularly the cardiac troponin. Their expert consensus
document makes clear that sensitive troponin assays are not
specific for myocardial infarction (MI) or acute coronary syndrome
(ACS), rather only for myonecrosis that may occur in multiple
acute or chronic conditions.
Their admonition to order troponin “only if clinically indi-
cated,” however, is likely to fall on deaf ears. Physicians order
troponin for as many as 50% of all admitted patients (2) because
symptoms and electrocardiography are often nondiagnostic, and
